Matheson Justin, Saini Harseerat, Haines-Saah Rebecca, Sanches Marcos, Sloan Matthew E, Zaweel Adam, Hassan Ahmed, Buckley Leslie, Porathl Amy, MacKillop James, Hendershot Christian S, Kloiber Stefan, Le Foll Bernard
Institute for Mental Health Policy Research, Centre for Addiction and Mental Health.
Human Biology Program, Faculty of Arts and Sciences, University of Toronto.
Cannabis. 2025 Jul 15;8(2):67-84. doi: 10.26828/cannabis/2025/000309. eCollection 2025.
The diversity and potency of cannabis products have increased in recent years, underscoring the importance of understanding which products are being used and why. Patients with substance use disorders (SUDs) use have a high prevalence of risky cannabis use, making it especially important to understand use patterns in this group. We aimed to first describe cannabis product characteristics and then explore reasons for choosing products in our sample.
In this mixed-methods study, 472 adults who self-reported accessing SUD treatment and lifetime cannabis use completed an online survey. A subset of 22 participants completed in-depth interviews. Quantitative results focused on describing cannabis use characteristics (e.g., product types) among participants reporting past-year cannabis use (current use group) or lifetime cannabis use but no use in past year (past use group), while qualitative descriptive analysis was used to describe reasons for choosing products among participants who were currently using cannabis.
Across medical and non-medical use of cannabis, dried flower and smoked cannabis formulations were most used (e.g., 89% of the current use group reported smoking cannabis for non-medical purposes), followed by edibles (e.g., 53% of the current use group used edible formulations of cannabis for non-medical purposes), though there was considerable use of higher-potency products such as concentrates and dabs (e.g., 11% of the current use group had used dabs for non-medical purposes). Our qualitative analysis found that almost all participants were motivated by THC content when purchasing products, yet sometimes perceived medical benefits or harm reduction were reasons for using certain products (especially CBD-dominant products), while sometimes other factors (e.g., convenience, familiarity) were influential.
Cannabis use characteristics (including motives for choosing products) are complex and nuanced in patients accessing SUD treatment. More work is needed to understand longitudinal relationships between use of different cannabis products and both harms and potential benefits.
近年来,大麻产品的多样性和效力有所增加,这凸显了了解正在使用哪些产品以及原因的重要性。患有物质使用障碍(SUDs)的患者中,危险大麻使用的患病率很高,因此了解该群体的使用模式尤为重要。我们的目标是首先描述大麻产品特征,然后探究我们样本中选择产品的原因。
在这项混合方法研究中,472名自我报告接受SUD治疗且有终生大麻使用史的成年人完成了一项在线调查。22名参与者的子集完成了深入访谈。定量结果侧重于描述报告过去一年使用大麻的参与者(当前使用组)或有终生大麻使用史但过去一年未使用大麻的参与者(过去使用组)中的大麻使用特征(例如,产品类型),而定性描述性分析用于描述当前使用大麻的参与者中选择产品的原因。
在大麻的医疗和非医疗用途中,干花和 smoked 大麻制剂使用最为广泛(例如,89%的当前使用组报告出于非医疗目的吸食大麻),其次是食用大麻制品(例如,53%的当前使用组出于非医疗目的使用食用大麻制剂),不过浓缩物和大麻脂等高效力产品也有大量使用(例如,11%的当前使用组出于非医疗目的使用过大麻脂)。我们的定性分析发现,几乎所有参与者在购买产品时都受四氢大麻酚(THC)含量的驱动,但有时感知到的医疗益处或危害降低是使用某些产品(尤其是以大麻二酚(CBD)为主的产品)的原因,而有时其他因素(例如,便利性、熟悉度)也有影响。
在接受SUD治疗的患者中,大麻使用特征(包括选择产品的动机)复杂且细微。需要开展更多工作来了解不同大麻产品的使用与危害及潜在益处之间的纵向关系。